COMPARISON OF THE EFFECTIVENESS OF FLUNARIZINE, PROPRANOLOL, AND PETASITES IN MANAGING PAIN SEVERITY AND DISABILITY IN MIGRAINE PATIENTS
Main Article Content
Keywords
Flunarizine, propranolol, petasites, migraine pain
Abstract
Objectives: To Compare the Effectiveness of Flunarizine, Propranolol, and Petasites in Managing Pain Severity and Disability in Migraine Patients.
Materials and Methods: Following ethical approval from Lady Reading Hospital, Peshawar, and obtaining informed consent, 93 patients meeting the inclusion criteria were enrolled. Participants were divided into three groups: Group A (flunarizine), Group B (propranolol), and Group C (petasites). Pain and disability were assessed using the Visual Analogue Scale (VAS) and the Migraine Disability Assessment Test (MIDAS) before and after two weeks of treatment. Pain severity on the VAS was categorized from mild to very severe, while MIDAS classified disability into four grades. Data were collected via a predesigned questionnaire and analyzed using SPSS Version 25.
Results: A total of 93 patients (mean age 40.82±12.14 years) were studied, with 32.3% males and 67.7% females. Age distribution was 33.3% (22–30 years), 37.6% (31–50 years), and 29.0% (>50 years). Post-treatment, significant reductions in Visual Analogue Scale and MIDAS scores were observed across Groups A, B, and C (p=0.00).
Conclusion: Flunarizine, propranolol, and petasites effectively manage migraine pain and disability, with flunarizine being most effective, followed by propranolol and petasites. These findings guide clinicians in choosing treatments, though further research on long-term outcomes is needed.
References
2. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiological reviews. 2017;97(2):553-622.
3. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health. 2009;12(1):55-64.
4. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. Springer; 2015. p. 1-3.
5. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache: The Journal of Head and Face Pain. 2018;58(5):700-14.
6. Lateef TM, Cui L, Nakamura E, Dozier J, Merikangas K. Accuracy of family history reports of migraine in a community‐based family study of migraine. Headache: The Journal of Head and Face Pain. 2015;55(3):407-12.
7. Freitag FG, Shumate D. Current and investigational drugs for the prevention of migraine in adults and children. CNS drugs. 2014;28:921-7.
8. Huang T-C, Lai T-H, Wang SJ, Wang PJ, Wang YF, Lee LH, et al. Medical treatment guidelines for preventive treatment of migraine. Acta Neurol Taiwanica. 2017;26:33-53.
9. Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):313-23.
10. Urits I, Gress K, Charipova K, Zamarripa AM, Patel PM, Lassiter G, et al. Pharmacological options for the treatment of chronic migraine pain. Best Practice & Research Clinical Anaesthesiology. 2020;34(3):383-407.
11. Singh RK, Pandey SK, Singh S, Chittoda A, Chaudhari SA. Currently Available Interventions for the Management of Migraine Pain. Management of Migraine Pain: Emerging Opportunities and Challenges: Springer; 2024. p. 191-227.
12. Dayal R, Sulindro AD. Prophylaxis of Migraine Protocols and Options. Migraine: Emerging Innovations and Treatment Options. 2021:51-73.
13. Rajapakse T, Gantenbein AR. Nutraceuticals in migraine. Handbook of Clinical Neurology. 2024;199:125-44.
14. Cauffield JS, Chen JJ. Neurological conditions. Principles and practice of botanicals as an integrative therapy: CRC Press; 2019. p. 203-20.
15. Rau JC, Dodick DW. Other preventive anti-migraine treatments: ACE inhibitors, ARBs, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists. Current Treatment Options in Neurology. 2019;21:1-28.
16. Singhal S. An open label, randomized comparison of propranolol, flunarizine and topiramate in migraine prophylaxis: Rajiv Gandhi University of Health Sciences (India); 2008.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Noor Javed
MBBS, Khyber Medical College, Peshawar, Pakistan
Dr Noor Ullah
Post Graduate Resident Neurosurgery, Ďepartment of Neurosurgery, Lady Reading Hospital, Peshawar, Pakistan
Dr Ali Ahsan Mufti
HOD & Associate Professor, Jinnah Medical College Peshawar & Consultant Psychiatrist at Ibadat Hospital & Horizon NGO for Mental Health, Pakistan
Kaukab Fatima
Senior Registrar, Department of Neurology, Bashir Hospital Sialkot, Pakistan
Dr Ghulam Mustafa
Associate Professor, Neurosurgery Department, Bolan Medical College, Pakistan
Dr Mian Mukhtar ul Haq
Associate Professor, Department of Psychiatry, MTI Lady Reading Hospital Peshawar, Pakistan